If you told a biologist 15 years ago that a byproduct of the citric acid cycle could shut down inflammation, they’d probably raise an eyebrow. That’s exactly what’s happening with itaconate, a small molecule that has quietly become one of the most talked-about players in immunometabolism.
This post breaks down what itaconate does, how it works at the molecular level, and why researchers think it could eventually lead to treatments for conditions as different as sepsis, inflammatory bowel disease, autoimmune disorders, and even cancer.
What is itaconate?
Itaconate is produced inside mitochondria by an enzyme called ACOD1 (also known as IRG1). When immune cells, particularly macrophages, detect a threat, ACOD1 kicks in and converts cis-aconitate, a citric acid cycle intermediate, into itaconate.
For a long time, scientists considered itaconate to be just a metabolic waste product. The thinking was: immune cells ramp up glycolysis during activation, reshape their TCA cycle, and itaconate is what spills out. That view turned out to be wrong. Itaconate isn’t waste. It’s a signal.
Two ways itaconate modifies proteins
The interesting part is not that itaconate exists, but what it does to other proteins in the cell. Research has identified two main types of modifications:
S-itaconation
This is an irreversible reaction. The alpha, beta-unsaturated double bond in itaconate undergoes Michael addition with cysteine residues on target proteins. Once a protein gets S-itaconated, the modification sticks.
Several well-studied targets illustrate why this matters:
- KEAP1: When itaconate modifies KEAP1, the protein can no longer target NFE2L2 (also called NRF2) for degradation. NFE2L2 builds up, moves into the nucleus, and switches on a suite of antioxidant and anti-inflammatory genes. This is probably the best-characterized itaconate mechanism.
- STING1: S-itaconation of STING1 blocks its ability to trigger IRF3-dependent interferon signaling. This means itaconate can dampen the type I interferon response during certain infections.
- TBK1: Similar to STING1, modifying TBK1 disrupts downstream signaling cascades that feed into inflammatory gene expression.
- JAK1: Itaconate modification of JAK1 interferes with STAT activation, reducing cytokine signaling that normally amplifies inflammation.
- NLRP3: The NLRP3 inflammasome is a multi-protein complex that, once assembled, produces IL-1 beta and drives pyroptosis (a form of inflammatory cell death). Itaconate blocks the assembly step.
- GSDMD: Gasdermin D is the pore-forming protein that executes pyroptosis. S-itaconation of GSDMD plugs the pore mechanism, preventing cells from bursting and releasing inflammatory contents.
These targets span multiple inflammatory pathways. Hit enough of them simultaneously and you get broad, coordinated anti-inflammatory activity without needing to target each pathway individually.
K-itaconation
This one works differently. Itaconate is first converted to itaconyl-CoA, which then serves as a substrate for lysine acyltransferases. The result is a reversible lysine modification on glycolytic enzymes.
Unlike S-itaconation, K-itaconation is transient. Cells can add and remove it. The effect is still the same general direction, though: metabolic reprogramming that pushes the cell toward a less inflammatory, more tissue-repair-oriented state.
The dual personality problem
Here’s something that makes the field tricky. The body’s own endogenous itaconate doesn’t always act as an anti-inflammatory. Under some conditions, it can do the opposite.
When endogenous itaconate inhibits succinate dehydrogenase (SDH) in the TCA cycle, mitochondrial function shifts. This can lead to release of mitochondrial RNA, which activates the cGAS-STING1 pathway. It can also affect PRDX5, increasing mitochondrial reactive oxygen species that further feed into cGAS-STING1 signaling. The net result: enhanced type I interferon responses.
But when you add exogenous itaconate derivatives, particularly 4-octyl itaconate (4-OI), the story flips. 4-OI modifies STING1 and JAK1 in ways that suppress interferon and inflammatory pathways.
This context-dependent duality is important. It means researchers need to be careful when interpreting results from itaconate intervention studies. The same molecule can push in both directions depending on the situation.
Therapeutic applications
Preclinical data across several disease models makes a compelling case for itaconate-based therapies.
Sepsis
In animal models of sepsis, 4-OI prevents lethal inflammation. The mechanisms include suppressed inflammasome activation, reduced pyroptosis, and decreased thrombus formation. Sepsis remains one of the leading causes of death in intensive care units, and current treatments are largely supportive. A drug that targets multiple inflammatory cascades at once would address a real gap.
Inflammatory bowel disease (IBD)
In models of colitis, itaconate derivatives protect the intestinal epithelium by blocking GSDMD- and GSDME-mediated cell death. The gut barrier stays intact, bacterial translocation drops, and disease severity decreases. This isn’t limited to one cell type or pathway. It’s a layer of protection across the epithelial layer.
Neurodegenerative diseases
Microglia, the immune cells of the central nervous system, also produce itaconate via ACOD1. In mouse models of Alzheimer’s disease and Parkinson’s disease, itaconate treatment dampens microglial activation, reduces oxidative stress (through NFE2L2 stabilization), and improves neuronal survival. The blood-brain barrier is a challenge for any therapeutic, but the fact that the brain’s own immune cells use this pathway suggests an endogenous protective mechanism worth amplifying.
Autoimmune diseases
In systemic lupus erythematosus (SLE) models, 4-OI reduces the type I interferon signature that drives disease pathology. In rheumatoid arthritis models, itaconate reprograms the metabolism of synovial fibroblasts and suppresses their invasive activity. Both effects happen without broadly suppressing the immune system the way current immunosuppressants do, which is an attractive property.
Cancer immunotherapy
The picture in cancer is more complicated. Itaconate modulates dendritic cell antigen presentation, influences immune checkpoint stability, and alters tumor cell metabolism. In some contexts, it might help immune cells recognize and attack tumors. In others, the anti-inflammatory effects could suppress anti-tumor immunity. Researchers are actively figuring out when and how itaconate derivatives could be combined with checkpoint inhibitors or other immunotherapies.
How do we even study this?
One of the bottlenecks has been identifying which proteins get modified by itaconate in living cells. Several chemical proteomics tools have changed that:
- ITalk: A chemical probe that labels S-itaconated proteins, allowing researchers to pull them out of complex mixtures and identify them by mass spectrometry.
- 1-OH-Az: Another activity-based probe with different chemoselectivity, useful for catching modifications that ITalk might miss.
- Thermal proteome profiling (TPP): Measures changes in protein thermal stability after itaconate treatment. Proteins that become more or less stable are likely direct targets.
Using these tools, researchers have mapped hundreds of itaconate modification sites across multiple signaling pathways. That’s a lot of potential drug targets.
What comes next
There are real challenges. Itaconate itself has poor pharmacokinetic properties: it doesn’t last long in the body, doesn’t distribute well to tissues, and cell membranes aren’t particularly permeable to it. Derivatives like 4-OI and dimethyl itaconate (DI) were developed partly to address these issues, but they come with their own limitations.
Drug delivery is another open question. How do you get enough itaconate or its derivatives to the right tissue at the right time? Nanoparticles, prodrugs, and tissue-targeted delivery systems are all being explored.
Then there’s the question I mentioned earlier about the dual effects. Any clinical trial design has to account for the possibility that itaconate-based treatments could enhance interferon signaling in some patients while suppressing it in others. Biomarker development will matter.
Bottom line
Itaconate sits at an interesting intersection. It’s a metabolite that does the work of a signaling molecule. It modifies proteins covalently but does so with enough selectivity to produce coordinated biological effects rather than chaos. And it touches enough disease-relevant pathways that the therapeutic potential is hard to ignore.
The field has moved fast over the past decade. What started as a curious observation in activated macrophages now has its own vocabulary (itaconation), its own toolkits, and a growing pipeline of potential clinical applications. Whether that translates into approved drugs is still an open question, but the biology is solid enough to keep pushing.
Frequently Asked Questions
What is itaconate?
Itaconate is a small molecule produced in mitochondria by the enzyme ACOD1. It’s generated from cis-aconitate, an intermediate in the citric acid cycle, and it acts as a signaling molecule that modulates inflammation and cellular metabolism.
How does itaconate differ from other immune-signaling metabolites?
Most metabolites involved in immune signaling either provide energy or act as precursors for other molecules. Itaconate does neither. It directly modifies proteins through covalent attachment, changing how those proteins function. That’s more like what a drug does than what a metabolite typically does.
What is S-itaconation?
S-itaconation is an irreversible chemical reaction where itaconate attaches to cysteine residues on proteins through Michael addition. This modification can block or alter protein function. Targets include KEAP1, STING1, NLRP3, and GSDMD.
What is K-itaconation?
K-itaconation is a reversible modification of lysine residues, mediated by itaconyl-CoA. Unlike S-itaconation, cells can remove it, making it more like a regulatory switch than a permanent off button.
Can endogenous itaconate promote inflammation?
Yes, in certain contexts. When endogenous itaconate inhibits succinate dehydrogenase, it can trigger mitochondrial RNA release and reactive oxygen species production, which activate cGAS-STING1 signaling and enhance type I interferon responses. This is different from the anti-inflammatory effects seen with exogenous itaconate derivatives.
What is 4-octyl itaconate (4-OI)?
4-OI is a cell-permeable derivative of itaconate designed to overcome the poor pharmacokinetic properties of native itaconate. It’s widely used in preclinical studies and has shown therapeutic effects in models of sepsis, colitis, neurodegeneration, and autoimmune disease.
Are there any itaconate-based drugs in clinical trials?
As of now, no itaconate-based drug has entered Phase III clinical trials. The research is primarily at the preclinical stage. Drug delivery, pharmacokinetics, and the dual effects of itaconate are active areas of investigation.
Why is itaconate relevant to cancer?
Itaconate modulates dendritic cell antigen presentation, immune checkpoint stability, and tumor cell metabolism. These effects could potentially improve how immune cells recognize and attack tumors, making itaconate derivatives candidates for combination with existing immunotherapies.